Lably
Skip to content

Homotaurine

  • 2 min read
  • 2 chapters

Related on Lably

Through Alzheimer's disease

Homotaurine was investigated in a Phase III clinical trial as a potential treatment for Alzheimer's disease (AD) that did not show efficacy. However, post-hoc analyses have shown positive and significant effects of homotaurine on secondary endpoints and subgroups of patients, including a reduction in hippocampal volume loss and lower decline in memory function in the overall cohort, as well as a reduction in global cognitive decline in APOE4 allele carriers, suggesting a disease-modifying effect. A study in cognitive impairment done in 2018 did show positive benefits.

Homotaurine is currently in a phase 3 study with expected FDA approval as the first disease modifying drug for AD.

Medical use

Acamprosate (N-acetyl homotaurine) was approved by the FDA in 2004 to treat alcohol dependence.

Sign in to keep reading

One more chapter is free with a Lably account.

More in Chemistry